Okazaki Ryo
Nihon Rinsho. 2015 Oct;73(10):1740-5.
This article reviews the treatment strategy for the secondary osteoporosis excluding those caused by diabetes, CKD, endocrine disorders, or glucocorticoid, which proceeding articles deal with. Among numerous possible causes for such secondary osteoporosis, the author has selected osteogenesis imperfecta (OI), osteoporosis associated with gastrectomy or bariatric surgery, inflammatory bowel diseases (IBD), and chronic obstructive pulmonary disease (COPD). For OI, current standard treatment is bisphosphonates (BPs), of which efficacy for fracture inhibition has recently been of issue. Other treatment modalities, e.g. PTH, have just been explored. Osteoporosis associated with gastrectomy, bariatric surgery or IBD, have been treated with vitamin D, calcium, and BPs. Despite high fracture rates, there are almost no treatment data for osteoporosis associated with COPD.
本文回顾了继发性骨质疏松症的治疗策略,但不包括由糖尿病、慢性肾脏病、内分泌紊乱或糖皮质激素引起的继发性骨质疏松症,后续文章将对这些内容进行讨论。在导致此类继发性骨质疏松症的众多可能原因中,作者选择了成骨不全症(OI)、与胃切除术或减肥手术相关的骨质疏松症、炎症性肠病(IBD)以及慢性阻塞性肺疾病(COPD)。对于成骨不全症,目前的标准治疗方法是双膦酸盐(BPs),其抑制骨折的疗效最近受到了质疑。其他治疗方式,如甲状旁腺激素(PTH),才刚刚开始探索。与胃切除术、减肥手术或炎症性肠病相关的骨质疏松症,已采用维生素D、钙和双膦酸盐进行治疗。尽管慢性阻塞性肺疾病相关骨质疏松症的骨折发生率很高,但几乎没有相关治疗数据。